Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Cardone, Luca ^a,d   Bardelli, Alberto ^b,c   Avvedimento, Vittorio Enrico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLUCOSE; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO 4; UNCLASSIFIED DRUG; WNT PROTEIN;

ADAPTATION; ALLELE; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST EPITHELIUM; CATALASE GENE; CONTROLLED STUDY; EGFR GENE; GENE; GENE EXPRESSION; GENE FREQUENCY; GLUCOSE DEPRIVATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; MNSOD GENE; NUTRIENT LIMITATION; ONCOGENE; ONCOGENE K RAS; OXIDATIVE STRESS; PHYSICAL TOLERANCE; PIK3CA GENE; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADENOSINE TRIPHOSPHATE; ALLELES; AMP-ACTIVATED PROTEIN KINASES; ANTIOXIDANTS; BETA CATENIN; CELL DEATH; CELL LINE; EPITHELIAL CELLS; GLUCOSE; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MAMMARY GLANDS, HUMAN; MUTATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTORS;

EID: 84861470369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037526     Document Type: Article

References (47)

1. Gatenby RA, Gillies RJ, (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8: 56-61.
2. DeBerardinis RJ, (2008) Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 10: 767-777.
3. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, et al. (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325: 1555-1559.
4. Kalaany NY, Sabatini DM, (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731.
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
6. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
7. Karakas B, Bachman KE, Park BH, (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94: 455-459.
8. Holbro T, Hynes NE, (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217.
9. Mendelsohn J, Baselga J, (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385.
10. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
11. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923.
12. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, et al. (2004) Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101-9104.
13. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, et al. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A 105: 20864-20869.
14. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
15. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
16. Carling D, (2004) The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29: 18-24.
17. Shackelford DB, Shaw RJ, (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
18. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, et al. (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11: 554-565.
19. Wu Y, Song P, Xu J, Zhang M, Zou MH, (2007) Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 282: 9777-9788.
20. Choi SL, Kim SJ, Lee KT, Kim J, Mu J, et al. (2001) The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 287: 92-97.
21. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA, (2009) Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 4: e4771.
22. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, et al. (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33: 237-247.
23. Dansen TB, (2011) Forkhead Box O transcription factors: key players in redox signaling. Antioxid Redox Signal 14: 559-561.
24. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, et al. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321.
25. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC, (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282: 27298-27305.
26. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, et al. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184.
27. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, et al. (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 23: 4802-4812.
28. Gabrielli A, Avvedimento EV, Krieg T, (2009) Scleroderma. N Engl J Med 360: 1989-2003.
29. Wang Q, Liang B, Shirwany NA, Zou MH, (2011) 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One 6: e17234.
30. Ennen M, Minig V, Grandemange S, Touche N, Merlin JL, et al. (2011) Regulation of the high basal expression of the manganese superoxide dismutase gene in aggressive breast cancer cells. Free Radic Biol Med 50: 1771-1779.
31. Nelson KK, Ranganathan AC, Mansouri J, Rodriguez AM, Providence KM, et al. (2003) Elevated sod2 activity augments matrix metalloproteinase expression: evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 9: 424-432.
32. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, et al. (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874.
33. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, et al. (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476: 346-350.
34. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB, (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54-61.
35. Gillies RJ, Robey I, Gatenby RA, (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 (Suppl 2): 24S-42S.
36. Shaw RJ, (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598-608.
37. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, et al. (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173.
38. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
39. Blancher C, Moore JW, Robertson N, Harris AL, (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61: 7349-7355.
40. Shaw RJ, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
41. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr, (2003) TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 4: 147-158.
42. van der Vos KE, Coffer PJ, (2008) FOXO-binding partners: it takes two to tango. Oncogene 27: 2289-2299.
43. Calnan DR, Brunet A, (2008) The FoxO code. Oncogene 27: 2276-2288.
44. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, et al. (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231.
45. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262-4266.
46. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, et al. (2002) ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277: 22692-22698.
47. Cassano S, Agnese S, D'Amato V, Papale M, Garbi C, et al. (2010) Reactive oxygen species, Ki-Ras, and mitochondrial superoxide dismutase cooperate in nerve growth factor-induced differentiation of PC12 cells. J Biol Chem 285: 24141-24153.